$CRYM
Cryomass Technologies, Inc. Stock $crym

$crym Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023088849 Filed on November 20, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$5.000K	$0.00	$0.00
YoY Change
Cost Of Revenue	$5.000K		$0.00
YoY Change
Gross Profit	$0.00		$0.00
YoY Change
Gross Profit Margin	0.0%
Selling, General & Admin	$866.4K	$470.0K	$4.948M
YoY Change	-82.49%	-5.38%	359.17%
% of Gross Profit
Research & Development	$0.00		$0.00
YoY Change
% of Gross Profit
Depreciation & Amortization	$29.22K	$13.08K	$91.50K
YoY Change	-68.07%	-40.12%	319.15%
% of Gross Profit
Operating Expenses	$1.616M	$1.373M	$5.514M
YoY Change	-70.69%	9.53%	139.51%
Operating Profit	-$1.616M	-$1.373M	-$5.514M
YoY Change	-70.69%	9.53%	139.51%
Interest Expense	-$201.7K	$109.3K	-$119.4K
YoY Change	68.97%	330.15%	-88.48%
% of Operating Profit
Other Income/Expense, Net		-$80.56K
YoY Change		-417.01%
Pretax Income	-$3.520M	-$1.450M	-$5.633M
YoY Change	-37.52%	18.04%	68.72%
Income Tax	$21.79K		-$21.79K
% Of Pretax Income
Net Earnings	-$3.542M	-$1.454M	-$5.612M
YoY Change	-36.89%	18.35%	-15.86%
Net Earnings / Revenue	-70830.6%
Basic Earnings Per Share		-$0.01
Diluted Earnings Per Share	-$0.02	-$0.01	-$0.03
COMMON SHARES
Basic Shares Outstanding	210.0M shares	206.2M shares	202.5M shares
Diluted Shares Outstanding		207.4M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$49.22K	$10.00K	$2.016M
YoY Change	-97.56%	-99.68%	-65.08%
Cash & Equivalents	$49.22K	$9.485K	$2.016M
Short-Term Investments
Other Short-Term Assets	$94.75K	$210.0K	$150.4K
YoY Change	-37.02%	53.69%	-80.14%
Inventory
Prepaid Expenses	$94.75K	$190.8K	$128.7K
Receivables	$8.550K
Other Receivables	$0.00
Total Short-Term Assets	$152.5K	$222.1K	$2.166M
YoY Change	-92.96%	-93.2%	-66.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$723.1K	$736.1K	$525.9K
YoY Change	37.5%	110.58%	133.71%
Goodwill			$1.190M
YoY Change			0.0%
Intangibles	$96.91K	$114.0K	$3.981M
YoY Change	-97.57%
Long-Term Investments			$10.30M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$820.0K	$850.2K	$5.696M
YoY Change	-85.61%	-91.31%	-37.08%
TOTAL ASSETS
Total Short-Term Assets	$152.5K	$222.1K	$2.166M
Total Long-Term Assets	$820.0K	$850.2K	$5.696M
Total Assets	$972.5K	$1.072M	$7.863M
YoY Change	-87.63%	-91.78%	-49.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.236M	$1.730M	$1.288M
YoY Change	73.57%	40.08%	-31.52%
Accrued Expenses
YoY Change
Deferred Revenue	$20.00K
YoY Change
Short-Term Debt	$0.00	$386.5K	$0.00
YoY Change
Long-Term Debt Due	$237.5K	$230.0K
YoY Change
Total Short-Term Liabilities	$2.494M	$1.980M	$1.288M
YoY Change	93.56%	60.3%	-31.55%
LONG-TERM LIABILITIES
Long-Term Debt	$3.068M	$2.430M	$2.000M
YoY Change	53.39%	21.5%	1029.43%
Other Long-Term Liabilities	$1.260M	$80.00K
YoY Change
Total Long-Term Liabilities	$4.328M	$2.510M	$2.000M
YoY Change	116.39%	25.5%	1029.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.494M	$1.980M	$1.288M
Total Long-Term Liabilities	$4.328M	$2.510M	$2.000M
Total Liabilities	$6.822M	$4.490M	$3.288M
YoY Change	107.44%	38.8%	59.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$51.97M	-$48.43M	-$39.01M
YoY Change	33.21%	44.99%	36.46%
Common Stock	$210.0K	$210.0K	$202.7K
YoY Change	3.64%	3.71%	2.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.849M	-$3.418M	$4.574M
YoY Change
Total Liabilities & Shareholders Equity	$972.5K	$1.072M	$7.863M
YoY Change	-87.63%	-91.78%	-49.54%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$3.542M	-$1.454M	-$5.612M
YoY Change	-36.89%	18.35%	-15.86%
Depreciation, Depletion And Amortization	$29.22K	$13.08K	$91.50K
YoY Change	-68.07%	-40.12%	319.15%
Cash From Operating Activities	-$595.0K	-$870.0K	-$913.5K
YoY Change	-34.87%	-1.69%	-63.9%
INVESTING ACTIVITIES
Capital Expenditures	$4.240K	$20.00K	$222.1K
YoY Change	-98.09%	-159.07%	-346.74%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$4.240K	-$20.00K	-$222.1K
YoY Change	-98.09%	-40.93%	58.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	632.4K	590.0K	21.87K
YoY Change	2791.54%	-68.29%	-99.73%
NET CHANGE
Cash From Operating Activities	-595.0K	-870.0K	-913.5K
Cash From Investing Activities	-4.240K	-20.00K	-222.1K
Cash From Financing Activities	632.4K	590.0K	21.87K
Net Change In Cash	33.16K	-300.0K	-1.114M
YoY Change	-102.98%	-131.86%	-120.12%
FREE CASH FLOW
Cash From Operating Activities	-$595.0K	-$870.0K	-$913.5K
Capital Expenditures	$4.240K	$20.00K	$222.1K
Free Cash Flow	-$599.2K	-$890.0K	-$1.136M
YoY Change	-47.23%	4.57%	-53.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q3	crym	Common Stock To Be Issued CommonStockToBeIssued		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	201998206	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	203440055	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56155
	dei	Entity Registrant Name EntityRegistrantName	CRYOMASS TECHNOLOGIES INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5051728
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1001 Bannock Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 612
	dei	Entity Address City Or Town EntityAddressCityOrTown	Denver
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80204
	dei	Local Phone Number LocalPhoneNumber	303-416-7208
	dei	City Area Code CityAreaCode	303
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	210032401	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9485	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2016057	usd
CY2023Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	21788	usd
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	21788	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	190845	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	128651	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	222118	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2166496	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	736149	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525855	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1190000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	114015	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3980582	usd
CY2023Q3	us-gaap	Assets Assets	1072282	usd
CY2022Q4	us-gaap	Assets Assets	7862933	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1729847	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1288465	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	229824	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1979671	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1288465	usd
CY2023Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	304029	usd
CY2023Q3	us-gaap	Liabilities Liabilities	4490084	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3288465	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	210032401	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	210032401	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	202651205	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	202651205	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	210033	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	202652	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	44797891	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43163579	usd
CY2022Q4	crym	Common Stock To Be Issued CommonStockToBeIssued	219765	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48425726	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39011528	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3417802	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4574468	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1072282	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7862933	usd
CY2023Q3	crym	Personnel Costs PersonnelCosts	869046	usd
CY2022Q3	crym	Personnel Costs PersonnelCosts	733233	usd
	crym	Personnel Costs PersonnelCosts	2360765	usd
	crym	Personnel Costs PersonnelCosts	1534885	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	313092	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	306037	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1099137	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	839818	usd
CY2023Q3	us-gaap	Legal Fees LegalFees	160987	usd
CY2022Q3	us-gaap	Legal Fees LegalFees	190693	usd
	us-gaap	Legal Fees LegalFees	564226	usd
	us-gaap	Legal Fees LegalFees	2337143	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	30179	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21832	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	299044	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	65495	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2031	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13361	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20518	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3653043	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1190000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1373304	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1253826	usd
	us-gaap	Operating Expenses OperatingExpenses	9179576	usd
	us-gaap	Operating Expenses OperatingExpenses	4797859	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1373304	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1253826	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9179576	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4797859	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	109302	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	19636	usd
	us-gaap	Interest Expense InterestExpense	245566	usd
	us-gaap	Interest Expense InterestExpense	90894	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	28740	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	45049	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	10944	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	77618	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-80562	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25413	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-234622	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13276	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1453866	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-1228413	usd
	us-gaap	Profit Loss ProfitLoss	-9414198	usd
	us-gaap	Profit Loss ProfitLoss	-4811135	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1453866	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1228413	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9414198	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4811135	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	207422054	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	201998206	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	205740483	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	203440055	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	13524320	usd
CY2022Q1	crym	Share Issuance In Exchange For Services ShareIssuanceInExchangeForServices	240625	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	140815	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2152305	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	11753455	usd
CY2022Q2	crym	Shares Issued From Warrants Exercised SharesIssuedFromWarrantsExercised	66151	usd
CY2022Q2	crym	Share Issuance In Exchange For Services ShareIssuanceInExchangeForServices	240626	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	69095	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1430418	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	10698909	usd
CY2022Q3	crym	Share Issuance In Exchange For Services ShareIssuanceInExchangeForServices	65626	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	214134	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-23409	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	89230	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1228413	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9816077	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4574468	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	65626	usd
CY2023Q1	crym	Common Stock Issued Vested Rs Us Value For Current Period Services CommonStockIssuedVestedRSUsValueForCurrentPeriodServices	50000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	62972	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1598526	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	3154540	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	20112	usd
CY2023Q2	crym	Common Stock Issued Vested Rs Us Value For Current Period Services CommonStockIssuedVestedRSUsValueForCurrentPeriodServices	79920	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	173631	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	179026	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6361806	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2754577	usd
CY2023Q3	crym	Common Stock Issued Vested Rs Us Value For Current Period Services CommonStockIssuedVestedRSUsValueForCurrentPeriodServices	1384	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	141905	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	387642	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	177989	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	65721	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1453866	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3417802	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9414198	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4811135	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	34964	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	72917	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	299044	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	65495	usd
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	5972	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1190000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3653043	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	546876	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	299140	usd
	crym	Common Stock Issued For Vested Rs Us For Current Period Service CommonStockIssuedForVestedRSUsForCurrentPeriodService	131304	usd
	crym	Stockbased Compensation For Vested Rs Us For Current Period Services StockbasedCompensationForVestedRSUsForCurrentPeriodServices	378508	usd
	crym	Stock Options Issued For Current Period Services StockOptionsIssuedForCurrentPeriodServices	177989	usd
	crym	Common Stock Issued For The Current Period Services CommonStockIssuedForTheCurrentPeriodServices	85738	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	62194	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-620746	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	219805	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-647415	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3211969	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3853376	usd
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	618831	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	124586	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	49236	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	53186	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74236	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-796603	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	387642	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	256876	usd
	crym	Proceeds From Common Stock Subscribed And To Be Issued ProceedsFromCommonStockSubscribedAndToBeIssued	16000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	875991	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1750000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1279633	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2006876	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2006572	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2643103	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2016057	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5772839	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9485	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3129736	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	221577	usd
	crym	Debt Discount Recognized From Warrants Issued In Conjunction With Notes Payable DebtDiscountRecognizedFromWarrantsIssuedInConjunctionWithNotesPayable	244747	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Nature of the Business</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CryoMass Technologies Inc. develops and licenses cutting-edge equipment and processes to refine harvested cannabis, hemp, and other premium crops. The company’s patented technology harnesses liquid nitrogen to reduce biomass and then efficiently isolate, collect and preserve delicate resin glands (trichomes) containing prized compounds like cannabinoids and terpenes. Building on this technology, CryoMass has engineered its premier Trichome Separation unit (CryoSift Separator™), optimized via patented cryogenic processes to rapidly capture intact, high-value cannabis and hemp trichomes (CryoSift™).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s principal office is located at 1001 Bannock St., Suite 612, Denver, CO 80204, and its telephone number is 303-416-7208. The Company’s website is www.cryomass.com. Information appearing on the website is not incorporated by reference into this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cryomass Technologies Inc is the parent company to wholly-owned subsidiaries Cryomass LLC, Cryomass California LLC, and 1304740 B.C. Unlimited Liability Company dba Cryomass Canada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 22, 2021, the Company entered into an Asset Purchase Agreement with Cryocann USA Corp, a California corporation (“Cryocann”), pursuant to which Company acquired substantially all the assets of Cryocann. The acquired assets included the patented cryogenic process titled “System and method for cryogenic separation of plant material” (US patent #10,864,525) for the reduction of biomass and efficient isolation, collection and preservation of delicate resin glands (trichomes) of harvested of hemp and cannabis, and potentially other high value trichome-rich plants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, we were granted an additional patent for our process from the Chinese Intellectual Property Office. In April 2022, we were granted another patent # 3,064,896 from the Canadian Intellectual Property Office. We currently are taking steps to gain further protection for our intellectual property through the European Union Intellectual Property Office and other international jurisdictions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first functional commercial unit, known as a CryoSift Separator™, has been installed at the premises of an operating partner, pursuant to a license and lease arrangement, in California.</p>
CY2023Q3	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	1757553	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9485	usd
	crym	Overhead Costs OverheadCosts	4200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3211969	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9414198	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48425726	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentrations of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Aside from this, the Company does not believe it is exposed to any unusual credit risk.</p>
	crym	Schedule Of Intangible Assets ScheduleOfIntangibleAssets	The estimated useful lives of intangible assets are detailed in the table below:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br/> Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Patent</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">120 Months</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">In-process research and development</td><td> </td> <td style="text-align: center">104 Months</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Internal use software</td><td> </td> <td style="text-align: center">26 Months</td></tr> </table>
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41684	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5400	usd
	crym	Income Taxes Description IncomeTaxesDescription	In accordance with ASC 740-10, for those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, our policy will be to record the largest amount of tax benefit that is more likely than not to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit will be recognized in the condensed consolidated financial statements.
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	736149	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525855	usd
CY2023Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	736149	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	525855	usd
CY2023Q3	us-gaap	Depreciation Depreciation	13077	usd
	us-gaap	Depreciation Depreciation	36283	usd
CY2023Q3	us-gaap	Goodwill Gross GoodwillGross	0	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	1190000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1190000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4230482	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	463424	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	-3653043	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	114015	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4181246	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	200664	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3980582	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17102	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	262761	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21832	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	65495	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	17103	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	68412	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	28500	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	114015	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	6600000	usd
CY2021	crym	Note Gross Amount NoteGrossAmount	3600000	usd
CY2022Q1	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	618831	usd
	crym	Territory License Fee TerritoryLicenseFee	750000	usd
CY2023Q3	crym	Territory License Fee TerritoryLicenseFee	100000	usd
	crym	Territory License Fee Agreement Description TerritoryLicenseFeeAgreementDescription	Territory License Fee, RubberRock will pay CryoMass monthly royalties (“Royalties”) equal to 25% of (“Gross Revenue”), which is the sum of all invoices issued by RubberRock to unaffiliated parties associated with or derived directly or indirectly from Permitted Toll Processing Activity and the resulting CryoSift™ produced on the Unit, including, but not limited to: (i) royalties, (ii) rentals, (iii) wholesale sales of resulting matter, and (iv) ingredients derived or extracted from plant matter processed through the Unit. Each calendar quarter, commencing with the fourth calendar quarter of 2023, (the “Reporting Quarter”), RubberRock shall pay Cryomass the greater of the Royalties due or the minimum quarterly royalties (“Minimum Quarterly Royalties”) to be paid within 30 days following each Reporting Quarter. The Minimum Quarterly Royalties Due to Licensor are: (a) for the first Reporting Quarter, the fourth calendar quarter of 2023, an aggregate of $100,000; (b) for each of the next three Reporting Quarters, the first, second and third calendar quarters of 2024, the amount of $478,333; (c) thereafter, for each Reporting Quarter, starting with the fourth calendar quarter of 2024, the amount of $750,000.
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	20000	usd
CY2023Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	80000	usd
CY2023Q2	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.12	pure
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	875991	usd
	crym	Proceeds From Note Payable ProceedsFromNotePayable	175000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	54128	usd
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.25
	crym	Subscriptions Agreements Description SubscriptionsAgreementsDescription	The fair value of the Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions at the dates of issuance, including the Company stock price ($0.13 for April subscription agreements, one of which is for Simon Langelier, $0.09 for May subscription agreements, $0.12 for June subscription agreement, $0.14 for July subscription agreement), exercise price ($0.25), term (4 years), historical volatility (152-153%), and risk-free rate (3.8% for April subscription agreements, 3.6% and 3.7% for May subscription agreements for Mario Gobbo and a private investor, respectively, 4.0% for June subscription agreement for Health Diplomats Pte Ltd, 4.2% for July subscription agreement).
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	244747	usd
	crym	Fair Value Of Promissory Notes FairValueOfPromissoryNotes	631243	usd
	crym	Debt Discount Recognized From Warrants Issued In Conjunction With Notes Payable DebtDiscountRecognizedFromWarrantsIssuedInConjunctionWithNotesPayable	244747	usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	386496	usd
CY2022Q3	us-gaap	Securities Loaned Or Sold Under Agreements To Repurchase Fair Value Disclosure SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseFairValueDisclosure	2000000	usd
CY2022Q3	us-gaap	Financing Receivable Modification To Total Financing Receivables Excluding Accrued Interest Percent FinancingReceivableModificationToTotalFinancingReceivablesExcludingAccruedInterestPercent	0.12	pure
	crym	Accrued Interest Percentage AccruedInterestPercentage	0.12	pure
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.25
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2175000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	48616	usd
CY2023Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	2126384	usd
CY2022Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	220500	shares
CY2022Q2	crym	Common Stock In Exchange For Services CommonStockInExchangeForServices	240626	shares
CY2022Q2	crym	Share Based Payment Arrangement Noncash Expense ShareBasedPaymentArrangementNoncashExpense	69095	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1453857	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.3
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	2760660	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.17
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	1877932	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.18
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2336585	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.21
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	755500	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.1
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	802000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.1
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2290085	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.21
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	14875	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.09
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2275210	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.2
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2200003	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.45
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1469511	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.27
CY2021Q4	crym	Weighted Average Remaining Contractual Term Outstanding WeightedAverageRemainingContractualTermOutstanding	P1Y10M24D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	1735529	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.49
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1933985	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.27
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	510000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.35
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	1135000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.28
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	50000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0.17
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1258985	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.2
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	69875	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.26
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	15000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.2
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1313860	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.3
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	13582	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	329193	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	317000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	1165600	usd
	crym	Unrecognized Stock Based Compensation UnrecognizedStockBasedCompensation	259532	usd
	crym	Unrecognized Stock Based Compensation UnrecognizedStockBasedCompensation	274241	usd
CY2022Q4	crym	Warrant Shares Outstanding WarrantSharesOutstanding	73950000	shares
CY2022Q4	crym	Weighted Average Remaining Contractual Term Outstanding WeightedAverageRemainingContractualTermOutstanding	P1Y
CY2022Q4	crym	Aggregate Fair Value Outstanding AggregateFairValueOutstanding	1867754	usd
CY2023Q1	crym	Warrant Shares Expired WarrantSharesExpired	15000000	shares
CY2023Q1	crym	Warrant Shares Outstanding WarrantSharesOutstanding	58950000	shares
CY2023Q1	crym	Weighted Average Remaining Contractual Term Outstanding WeightedAverageRemainingContractualTermOutstanding	P0Y10M24D
CY2023Q1	crym	Aggregate Fair Value Outstanding AggregateFairValueOutstanding	1867754	usd
CY2023Q2	crym	Warrant Shares Granted WarrantSharesGranted	2540550	shares
CY2023Q2	crym	Aggregate Fair Value Granted AggregateFairValueGranted	179026	usd
CY2023Q2	crym	Warrant Shares Expired WarrantSharesExpired	9500000	shares
CY2023Q2	crym	Warrant Shares Outstanding WarrantSharesOutstanding	51990550	shares
CY2023Q2	crym	Weighted Average Remaining Contractual Term Outstanding WeightedAverageRemainingContractualTermOutstanding	P0Y10M24D
CY2023Q2	crym	Aggregate Fair Value Outstanding AggregateFairValueOutstanding	2046780	usd
CY2023Q3	crym	Warrant Shares Granted WarrantSharesGranted	4589639	shares
CY2023Q3	crym	Aggregate Fair Value Granted AggregateFairValueGranted	203858	usd
CY2023Q3	crym	Warrant Shares Expired WarrantSharesExpired	1000000	shares
CY2023Q3	crym	Warrant Shares Outstanding WarrantSharesOutstanding	55580189	shares
CY2023Q3	crym	Weighted Average Remaining Contractual Term Outstanding WeightedAverageRemainingContractualTermOutstanding	P0Y10M24D
CY2023Q3	crym	Aggregate Fair Value Outstanding AggregateFairValueOutstanding	2250638	usd
CY2021Q4	crym	Warrant Shares Outstanding WarrantSharesOutstanding	80975898	shares
CY2021Q4	crym	Aggregate Fair Value Outstanding AggregateFairValueOutstanding	1867754	usd
CY2022Q1	crym	Warrant Shares Outstanding WarrantSharesOutstanding	80975898	shares
CY2022Q1	crym	Weighted Average Remaining Contractual Term Outstanding WeightedAverageRemainingContractualTermOutstanding	P1Y7M6D
CY2022Q1	crym	Aggregate Fair Value Outstanding AggregateFairValueOutstanding	1867754	usd
CY2022Q2	crym	Warrant Shares Exercised WarrantSharesExercised	-220500	shares
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y3M18D
CY2022Q2	crym	Warrant Shares Outstanding WarrantSharesOutstanding	80755398	shares
CY2022Q2	crym	Weighted Average Remaining Contractual Term Outstanding WeightedAverageRemainingContractualTermOutstanding	P1Y4M24D
CY2022Q2	crym	Aggregate Fair Value Outstanding AggregateFairValueOutstanding	1867754	usd
CY2022Q3	crym	Warrant Shares Expired WarrantSharesExpired	2500000	shares
CY2022Q3	crym	Warrant Shares Outstanding WarrantSharesOutstanding	78255398	shares
CY2022Q3	crym	Weighted Average Remaining Contractual Term Outstanding WeightedAverageRemainingContractualTermOutstanding	P1Y1M6D
CY2022Q3	crym	Aggregate Fair Value Outstanding AggregateFairValueOutstanding	1867754	usd
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.25
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Heldtomaturity Securities Debt Maturities Date HeldtomaturitySecuritiesDebtMaturitiesDate	2025-12-15
CY2023Q3	us-gaap	Financing Receivable Excluding Accrued Interest Nonaccrual Percent Past Due FinancingReceivableExcludingAccruedInterestNonaccrualPercentPastDue	0.12	pure
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.09
	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2027-11-03
CY2023Q3	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent		usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	205740483	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	207422054	shares
CY2022Q1	crym	Warrant Shares Exercised WarrantSharesExercised		shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
CY2022Q1	crym	Aggregate Fair Value Exercised AggregateFairValueExercised		usd
CY2022Q1	crym	Warrant Shares Expired WarrantSharesExpired		shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2023Q1	crym	Common Stock Issued For Prior Period Services CommonStockIssuedForPriorPeriodServices		usd
CY2023Q1	crym	Common Stock Issued For Vested Rs Us Value For Prior Period Services CommonStockIssuedForVestedRSUsValueForPriorPeriodServices		usd
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	crym	Common Stock Issued For Vested Rs Us For Current Period Service CommonStockIssuedForVestedRSUsForCurrentPeriodService		usd
	crym	Stockbased Compensation For Vested Rs Us For Current Period Services StockbasedCompensationForVestedRSUsForCurrentPeriodServices		usd
	crym	Stock Options Issued For Current Period Services StockOptionsIssuedForCurrentPeriodServices		usd
	crym	Common Stock Issued For The Current Period Services CommonStockIssuedForTheCurrentPeriodServices		usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable		usd
	crym	Proceeds From Common Stock Subscribed And To Be Issued ProceedsFromCommonStockSubscribedAndToBeIssued		usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
	crym	Debt Discount Recognized From Warrants Issued In Conjunction With Notes Payable DebtDiscountRecognizedFromWarrantsIssuedInConjunctionWithNotesPayable		usd
CY2022Q3	us-gaap	Depreciation Depreciation		usd
	us-gaap	Depreciation Depreciation		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2023Q1	crym	Warrant Shares Granted WarrantSharesGranted		shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2023Q1	crym	Aggregate Fair Value Granted AggregateFairValueGranted		usd
CY2023Q1	crym	Warrant Shares Exercised WarrantSharesExercised		shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
CY2023Q1	crym	Aggregate Fair Value Exercised AggregateFairValueExercised		usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2023Q1	crym	Aggregate Fair Value Expired AggregateFairValueExpired		usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2023Q2	crym	Warrant Shares Exercised WarrantSharesExercised		shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
CY2023Q2	crym	Aggregate Fair Value Exercised AggregateFairValueExercised		usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2023Q2	crym	Aggregate Fair Value Expired AggregateFairValueExpired		usd
CY2023Q3	crym	Warrant Shares Exercised WarrantSharesExercised		shares
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
CY2023Q3	crym	Aggregate Fair Value Exercised AggregateFairValueExercised		usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2023Q3	crym	Aggregate Fair Value Expired AggregateFairValueExpired		usd
CY2022Q1	crym	Warrant Shares Granted WarrantSharesGranted		shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2022Q1	crym	Aggregate Fair Value Granted AggregateFairValueGranted		usd
CY2022Q1	crym	Aggregate Fair Value Expired AggregateFairValueExpired		usd
CY2022Q2	crym	Warrant Shares Granted WarrantSharesGranted		shares
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2022Q2	crym	Aggregate Fair Value Granted AggregateFairValueGranted		usd
CY2022Q2	crym	Aggregate Fair Value Exercised AggregateFairValueExercised		usd
CY2022Q2	crym	Warrant Shares Expired WarrantSharesExpired		shares
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2022Q2	crym	Aggregate Fair Value Expired AggregateFairValueExpired		usd
CY2022Q3	crym	Warrant Shares Granted WarrantSharesGranted		shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2022Q3	crym	Aggregate Fair Value Granted AggregateFairValueGranted		usd
CY2022Q3	crym	Warrant Shares Exercised WarrantSharesExercised		shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
CY2022Q3	crym	Aggregate Fair Value Exercised AggregateFairValueExercised		usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2022Q3	crym	Aggregate Fair Value Expired AggregateFairValueExpired		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001533030

Files In Submission

Name	View Source	Status
0001213900-23-088849-index-headers.html	Edgar Link	pending
0001213900-23-088849-index.html	Edgar Link	pending
0001213900-23-088849.txt	Edgar Link	pending
0001213900-23-088849-xbrl.zip	Edgar Link	pending
crym-20230930.xsd	Edgar Link	pending
f10q0923ex31-1_cryomasstech.htm	Edgar Link	pending
f10q0923ex31-2_cryomasstech.htm	Edgar Link	pending
f10q0923ex32-1_cryomasstech.htm	Edgar Link	pending
f10q0923ex32-2_cryomasstech.htm	Edgar Link	pending
f10q0923_cryomasstech.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
crym-20230930_cal.xml	Edgar Link	unprocessable
crym-20230930_def.xml	Edgar Link	unprocessable
crym-20230930_lab.xml	Edgar Link	unprocessable
crym-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0923_cryomasstech_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRYM
Cryomass Technologies, Inc. Stock $crym

2023 Q4 Form 10-Q Financial Statement

#000121390023088849 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRYM Cryomass Technologies, Inc. Stock $crym

2023 Q4 Form 10-Q Financial Statement

#000121390023088849 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRYM
Cryomass Technologies, Inc. Stock $crym